Leo Bonifacio

Company: ​​Edesa Biotech Inc.

Job title: Director, Business Development

Seminars:

A Novel Target in Vitiligo: CxCL10 11:15 am

Vitiligo remains an area with a significant unmet need, in particular for new targeted systemic treatments The IFNγ-CXCL10-CXCR3 pathway offers new and exciting opportunities for addressing the condition, with CXCL10 playing an important role in apoptosis of melanocytes, and recruitment and positioning of effector T-cells EB06 is a novel anti-CXCL10 monoclonal antibody that is being…Read more

day: Day One Discovery Track AM